Should You Buy Spero Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Spero Therapeutics, Inc. (SPRO) occupies a solid middle-ground position with a Quality of Company score of 7.4/10. At the current market price of $1.13, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 5 of 8 CirclFi valuation models project upside for Spero Therapeutics, Inc. (SPRO) at $1.13 — the model consensus leans bullish, with a Quality Score of 7.4/10 and Value-Trap risk of 48/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Spero Therapeutics, Inc. (SPRO) in 2026?
What Is the Bull Case vs the Bear Case for Spero Therapeutics, Inc. (SPRO)?
| Bull case — $2.39 target (+111.8%) | Bear case — $0.65 target (-42.7%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Spero Therapeutics, Inc.'s rating of 7.4/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. |
| According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $2.39 (+111.8%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously. | According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $0.65 (-42.7%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry tailwind: platform technology validation could provide meaningful support for Spero Therapeutics, Inc.'s revenue and margin trajectory in the Biotechnology space. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +154.5% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry headwind: dilutive capital raises represents a meaningful risk for Spero Therapeutics, Inc. and its Biotechnology peers. |
How Does SPRO Compare to Its Biotechnology Peers?
Valuation data pages: BDTX · TWST · JAZZ · BNTX · ARWR · TLX · IMA · CMPX · HUMA · EXEL · INCY
Which Other Stocks Score Like SPRO on Quality?
Closest companies to SPRO’s Quality of Company score of 7.4/10, across all industries.
- DEO — Diageo plc (QOC 7.4) · analysis
- OCFC — OceanFirst Financial Corp. (QOC 7.4) · analysis
- EVI — EVI Industries, Inc. (QOC 7.4) · analysis
- TD — The Toronto-Dominion Bank (QOC 7.4) · analysis
- RSVR — Reservoir Media, Inc. (QOC 7.4) · analysis
- CLBK — Columbia Financial, Inc. (QOC 7.4) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does SPRO Appear In?
So Is Spero Therapeutics, Inc. (SPRO) Worth Buying in 2026?
Spero Therapeutics, Inc. at $1.13 is a genuine coin-flip in our framework. The 4–3 bull-bear split across 8 models, +154.5% model spread, and median fair value of $1.16 (+2.7% vs price) argue for a watchlist position rather than a high-conviction bet. Quality at 7.4/10 adds some comfort to the mix.
These are quantitative model outputs, not investment recommendations. Spero Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About SPRO Stock?
Should I buy SPRO stock right now?
Based on CirclFi's multi-model analysis, 5 of 8 models see upside for SPRO at $1.13. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.4/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Spero Therapeutics, Inc.?
Key risks include: an elevated Value Trap score of 48/100, suggesting apparent undervaluation may mask deteriorating fundamentals; wide model disagreement (270% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does SPRO compare to its competitors?
Among Biotechnology peers, SPRO holds a Quality Score of 7.4/10. Comparable companies include BDTX (QOC 7.5), TWST (QOC 7.4), JAZZ (QOC 7.6). The relative ranking helps investors identify whether SPRO offers better fundamental quality than alternatives in the same sector.
Is SPRO a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. SPRO's Quality Score of 7.4/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy SPRO at?
CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $0.65 to $2.39. At $1.13, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for SPRO.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad